Table 1. Characteristics of patients with LPR and HPR in the validation group.
| Variables | LPR group (n=17) | HPR group (n=22) | P |
|---|---|---|---|
| Clinical parameters | |||
| Age (years) | 51.94±10.37 | 63.91±8.20 | <0.001 |
| Male sex (%) | 94.1 | 63.6 | 0.052 |
| BMI (kg/m2) | 26.15±2.73 | 25.53±2.60 | 0.477 |
| Hypertension (%) | 58.8 | 72.7 | 0.497 |
| Hyperlipidemia (%) | 76.5 | 81.8 | 0.709 |
| Diabetes (%) | 29.4 | 36.4 | 0.740 |
| Family CAD history (%) | 17.6 | 27.3 | 0.704 |
| Current smoking (%) | 41.2 | 31.8 | 0.738 |
| LVEF | 56.62±9.69 | 58.86±8.68 | 0.459 |
| Medications | |||
| PPI (%) | 17.6 | 31.8 | 0.464 |
| Nitrates (%) | 100 | 100 | 1.000 |
| β-blockers (%) | 94.1 | 86.4 | 0.618 |
| ACEI (%) | 29.4 | 22.7 | 0.721 |
| ARB (%) | 23.5 | 36.4 | 0.494 |
| CCB (%) | 41.2 | 68.2 | 0.115 |
| Statins (%) | 100 | 95.5 | 1.000 |
| Laboratory parameters | |||
| WBC counts (109/L) | 7.49±1.56 | 6.95±1.48 | 0.284 |
| Hemoglobin (g/L) | 147.12±15.28 | 132.77±10.10 | 0.000 |
| Creatinine (μmol/L) | 80.89±14.67 | 78.14±17.59 | 0.606 |
| PCI parameters | |||
| No. of stents implanted | 1.76±1.15 | 2.05±0.95 | 0.409 |
| Left anterior descending artery | 58.8 | 50.0 | 0.748 |
| Platelet function parameters | |||
| VerifyNow P2Y12 (PRU), 1st day | 127.29±42.24 | 351.00±30.05 | <0.001 |
| VerifyNow P2Y12 (PRU), 2nd day | 122.65±32.23 | 338.91±34.26 | <0.001 |
Continuous variables are presented as mean ± SD and categorical variables as percentage of the subjects. BMI, body mass index; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; PPI, proton pump inhibitor; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; WBC, white blood cell; PRU, platelet reactivity unit; LPR, low platelet reactivity; HPR, high platelet reactivity.